trending Market Intelligence /marketintelligence/en/news-insights/trending/IZFb4xWPjMkofQ4w19Z4iw2 content esgSubNav
In This List

Roche hemophilia drug sees positive phase 3 study results

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Roche hemophilia drug sees positive phase 3 study results

Roche Holding Ltd.'s hemophilia A drug candidate met its primary- and- secondary endpoints in a phase 3 study.

ACE910, or emicizumab, showed a significant reduction in the number of bleeds over time in 12-year-old patients and older when compared to no prophylactic treatment.

The company also said it had resolved the thrombosis concerns raised earlier during the trial.